Study record
RTB101 Phase 3 respiratory-illness program (1024 participants)
Primary respiratory illness endpoint
Human — Adults, RTB101 Phase 3 program Tier 2 · Human clinical/functional RCT verification: verified
1. Species / populationAdult humans, RTB101 Phase 3 program, 1024 participants
2. Exposure, route, scheduleRTB101, oral, per Phase 3 protocol
3. Comparator & durationPlacebo; per Phase 3 protocol duration
4. Endpoint & numeric resultPrimary respiratory illness endpoint: 26% vs 25%, OR 1.07 -- no effect
5. What this study did NOT establishNo lifespan data; no effect on primary endpoint at Phase 3 scale
Full record
| Intervention(s) | RTB101 |
| Species | Human |
| Population | Adults, RTB101 Phase 3 program |
| Sample size | 1024 participants verification: verified_2026-07-11 |
| Exposure | RTB101, oral — Per Phase 3 trial protocol verification: verified_2026-07-11 |
| Comparator | Placebo |
| Duration | Per Phase 3 trial protocol (duration not detailed in the sourcing brief) |
| Endpoint | Primary respiratory illness endpoint |
| Evidence tier | Tier 2 · Human clinical/functional RCT |
| What was NOT established | Did not test lifespan. No effect on the pre-specified primary endpoint; does not support any respiratory-protection or longevity claim for RTB101 at the tested regimen, despite the earlier positive Phase 2b signal. |
Result values (as reported in sourcing brief)
| treatment arm | 26% |
| placebo arm | 25% |
| odds ratio | OR 1.07 |
| interpretation | No significant effect on the primary endpoint |
| verification | verification: verified_2026-07-11 |
Source citation
Verification status: verified This record was checked against its primary publication on 2026-07-11. PubMed/PMC/Lancet lookup; numbers cross-checked against abstract.Identifiers: PMID verified; DOI verified; PMC verified; trial registry ID not reported. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that does not apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
| trial name | RTB101 Phase 3 |
| pmid | 34095860 verified |
| doi | 10.1016/S2666-7568(21)00062-3 verified |
| journal | The Lancet Healthy Longevity 2021 |
| trial registry id | not reported not reported |
| pmc | PMC8102040 verified |
| authors | Mannick JB, et al. |
| year | 2021 |
| verified date | 2026-07-11 |
| verified method | PubMed/PMC/Lancet lookup; numbers cross-checked against abstract |
| verified note | Phase 3: n=1024 aged >=65, 10 mg RTB101 daily vs placebo, 16 wk winter season; DID NOT meet primary endpoint (no significant benefit) — MATCHES. |
| verification status | verified |
Funding / conflict of interest
not compiled in this proof-of-concept verification: verified_2026-07-11
Version 0.2.0-mvp · literature search date 2026-07-11 · editorial owner Nabus Research